201 related articles for article (PubMed ID: 32062061)
1. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.
Schmidt S; Liu Y; Hu ZH; Williams KM; Lazarus HM; Vij R; Kharfan-Dabaja MA; Ortí G; Wiernik PH; Weisdorf D; Kamble RT; Herzig R; Wirk B; Cerny J; Bacher U; Chaudhri NA; Nathan S; Farhadfar N; Aljurf M; Gergis U; Szer J; Seo S; Hsu JW; Olsson RF; Maharaj D; George B; Hildebrandt GC; Agrawal V; Nishihori T; Abdel-Azim H; Alyea E; Popat U; Sobecks R; Scott BL; Holter Chakrabarty J; Saber W
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1137-1143. PubMed ID: 32062061
[TBL] [Abstract][Full Text] [Related]
2. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
3. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?
Zeidner JF; Zahurak M; Rosner GL; Gocke CD; Jones RJ; Smith BD
Leuk Lymphoma; 2015 Jan; 56(1):128-34. PubMed ID: 24712979
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
DeFilipp Z; Ancheta R; Liu Y; Hu ZH; Gale RP; Snyder D; Schouten HC; Kalaycio M; Hildebrandt GC; Ustun C; Daly A; Ganguly S; Inamoto Y; Litzow M; Szer J; Savoie ML; Hossain N; Kharfan-Dabaja MA; Hamadani M; Reshef R; Bajel A; Schultz KR; Gadalla S; Gerds A; Liesveld J; Juckett MB; Kamble R; Hashmi S; Abdel-Azim H; Solh M; Bacher U; Lazarus H; Olsson R; Cahn JY; Grunwald MR; Savani BN; Yared J; Rowe JM; Cerny J; Chaudhri NA; Aljurf M; Beitinjaneh A; Seo S; Nishihori T; Hsu JW; Ramanathan M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2020 Mar; 26(3):472-479. PubMed ID: 31669399
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
6. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.
Chaudhury S; Sparapani R; Hu ZH; Nishihori T; Abdel-Azim H; Malone A; Olsson R; Hamadani M; Daly A; Bacher U; Wirk BM; Kamble RT; Gale RP; Wood WA; Hale G; Wiernik PH; Hashmi SK; Marks D; Ustun C; Munker R; Savani BN; Alyea E; Popat U; Sobecks R; Kalaycio M; Maziarz R; Hijiya N; Saber W
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1056-1064. PubMed ID: 26964698
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
Bar M; Radich J
J Natl Compr Canc Netw; 2013 Mar; 11(3):308-15. PubMed ID: 23486457
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
10. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
11. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
12. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
[TBL] [Abstract][Full Text] [Related]
13. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
14. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
15. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
Fernandez HF; Kharfan-Dabaja MA
Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
[TBL] [Abstract][Full Text] [Related]
17. Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.
Savoie ML; Bence-Bruckler I; Huebsch LB; Lalancette M; Hillis C; Walker I; Lipton JH; Forrest DL; Kim DDH
Leuk Res; 2018 Oct; 73():67-75. PubMed ID: 30227318
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors.
Yassine F; Reljic T; Moustafa MA; Iqbal M; Murthy HS; Kumar A; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):36-43. PubMed ID: 33789163
[TBL] [Abstract][Full Text] [Related]
19. Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.
Liberio N; Robinson H; Nugent M; Simpson P; Margolis DA; Malarkannan S; Keever-Taylor C; Thakar MS
Pediatr Blood Cancer; 2019 Nov; 66(11):e27950. PubMed ID: 31368194
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
